Health deep tech startup Mesh Bio partners Indonesian diagnostic lab

Health deep tech startup Mesh Bio partners Indonesian diagnostic lab
Image credit: PT Pramita

PT Pramita to use Singaporean company’s analytics engine.

By on

Indonesian health laboratory services company, PT Pramita (Pramita), has signed a memorandum of understanding (MoU) with Singapore-based Mesh Bio, a digital health deep tech startup, to use the latter's predictive analytics software for chronic disease management.

Targeting the healthcare burden of an ageing population, the two organisations will “strive to drive positive health outcomes through the digital transformation of preventive health services and medical check-ups”, a joint statement by the two companies said.

The MoU was signed by PT Pramita’s VP, Nabil Fachliansyah and Mesh Bio’s co-founder and CEO, Andrew Wu in the backdrop of a meeting between the trade and economic affairs ministers of Indonesia and Singapore.

The partnership will focus on Pramita using Mesh Bio’s proprietary software – DARA health intelligence platform.

Dr Wu said the platform was powered by an analytics engine that combines metabolic disease digital twins, data science and predictive analytics, which enables healthcare providers to deliver personalised preventive care with intelligent healthcare data.

He added that the solution will “enable precision patient intervention” to be delivered to a large population in Indonesia “in an affordable and scalable manner”.

According to a recent study on chronic diseases in Indonesia, published by The Lancet, amongst the top five leading risks contributing to health loss measured in disability-adjusted life years (DALYs) in 2019 were high systolic blood pressure, high fasting plasma glucose, high BMI (body mass index) and more.

These risk factors commonly lead to chronic conditions such as diabetes, obesity and hypertension.

Dr Nabil noted that due to this, the impetus to manage the burden of non-communicable diseases has become an “urgent health policy concern, especially so due to the high cost involved to treat and manage such diseases in a population that has increased its life expectancy by six to eight years on average since 1990”.

Talking about the MoU, he added: “We look forward to catalysing greater collaboration in the adoption of digital solutions within the healthcare industry, including exploring the possibilities of deep-tech solutions across other fields of medicine and healthcare services”. 

To reach the editorial team on your feedback, story ideas and pitches, contact them here.
© iTnews Asia

Most Read Articles